Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Nantong Changyou Pharmaceutical Technology, obtained approval from China's National Medical Products Administration to produce and market active pharmaceutical ingredient Vericiguat, according to a Shanghai Stock Exchange filing on Tuesday.

Vericiguat, which was originally developed by global pharmaceutical giant Merck Sharp & Dohme, is primarily indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction, who have been stabilized following recent decompensated heart failure treated intravenously.

The Chinese pharma company invested 3.6 million yuan into the research and development of the API, the filing said.